BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Feb. 06, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the...

Related Keywords

Vikram Bali ,Globenewswire Inc ,Bridgebio Pharma Inc ,Nasdaq ,Twitter ,Linkedin ,Bio Pharma ,Equity Plan ,Nasdaq Listing Rule ,Bio Contact ,Markets ,